Assessment of health-related quality of life (HRQoL) in triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial

被引：0
|
作者：
Hoffman, James E.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Lee, Hans C.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Maly, Joseph J.
Shah, Mansi R.
Baz, Rachid C.
DeVeaux, Michelle
Ivanescu, Cristina
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Inocencio, Timothy J.
Chi, Lei
Harnett, James
Ma, Qiufei
Jagannath, Sundar
机构：
[1] Univ Miami Hlth Syst, Miami, FL USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA
[3] Icahn Sch Med Mt Sinai, New York, NY USA
[4] Emory Univ, Sch Med, Atlanta, GA USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Indiana Univ, Simon Canc Ctr, Indianapolis, IN USA
[7] Indiana Univ, Roudebush VAMC, Indianapolis, IN USA
[8] Karmanos Canc Inst, Detroit, MI USA
[9] Norton Canc Inst, Louisville, KY USA
[10] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[12] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23185
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment
    Hoffman, James E.
    Bumma, Naresh
    Richter, Joshua
    Dhodapkar, Madhav V.
    Lee, Hans C.
    Suvannasankha, Attaya
    Houde, Christiane A.
    Maly, Joseph J.
    Shah, Mansi R.
    Baz, Rachid
    Namburi, Swathi
    Wu, Ka Lung
    Pianko, Matthew
    Ye, Jing Christine
    Lentzsch, Suzanne
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    Martinez Lopez, Joaquin
    DeVeaux, Michelle
    Ivanescu, Cristina
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Houvras, Yariv
    Inocencio, Timothy J.
    Chi, Lei
    Harnett, James
    Ma, Qiufei
    Jagannath, Sundar
    BLOOD, 2023, 142
  • [2] Pharmacokinetics (PK) and Immunogenicity of Linvoseltamab in Patients (pts) with Relapsed/ Refractory Multiple Myeloma (RRMM) in LINKER-MM1
    Hazra, Anasuya
    Lai, Ching-Ha
    Chokshi, Dhruti
    Houvras, Yariv
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    DiCioccio, A. Thomas
    Davis, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S57 - S57
  • [3] Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study
    Dhodapkar, Madhav
    Bumma, Naresh
    Richter, Joshua
    Lee, Hans
    Hoffman, James
    Suvannasankha, Attaya
    Lentzsch, Suzanne
    Shah, Mansi
    Zonder, Jeffrey
    Baz, Rachid
    Wu, Ka Lung
    Pianko, Matthew
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane Madeleine
    Munder, Markus
    Byun, Ja Min
    Martinez Lopez, Joaquin
    DeVeaux, Michelle
    Lorenc, Karen Rodriguez
    Kroog, Glenn
    Houvras, Yariv
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S172 - S172
  • [4] LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
    Lee, Hans C.
    Bumma, Naresh
    Richter, Joshua Ryan
    Dhodapkar, Madhav V.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Maly, Joseph J.
    Ye, Jing Christine
    Wu, Ka Lung
    DeVeaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Rodriguez-Lorenc, Karen
    Kroog, Glenn Scott
    Houvras, Yariv J.
    Jagannath, Sundar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1
    Suvannasankha, Attaya
    Lee, Hans
    Bumma, Naresh
    Dhodapkar, Madhav V.
    Richter, Joshua
    Hoffman, James E.
    Shah, Mansi
    Lentzsch, Suzanne
    Zonder, Jeffrey
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Wu, Ka Lung
    Pianko, Matthew
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Martinez Lopez, Joaquin
    DeVeaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Kroog, Glenn S.
    Houvras, Yariv
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S90 - S91
  • [6] Health-Related Quality of Life (HRQoL) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Are Triple-Class Exposed to an Immunomodulatory Agent, a Proteasome Inhibitor, and an Anti-CD38 Antibody
    Shah, Nina
    Vij, Ravi
    Roberts, Jenna S.
    Rajkovic, Ivana
    Silbermann, Rebecca
    Hillengass, Jens
    Dhanasiri, Sujith
    Braverman, Julia
    McMillan, Abigail
    Dhanda, Devender
    BLOOD, 2022, 140 : 13259 - 13261
  • [7] Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Jagannath, Sundar
    Lee, Hans C.
    Richter, Joshua Ryan
    Zonder, Jeffrey A.
    Hoffman, James E.
    Zhou, Zheng-Yi
    Horton, Viviana Garcia
    Fillbrunn, Mirko
    Wang, Hongjue
    Mattera, Matthew
    Ma, Qiufei
    Inocencio, Timothy J.
    Xu, Yingxin
    Bergrath, Evelien
    Harnett, James
    Roccia, Tito
    Kroog, Glenn Scott
    Rodriguez-Lorenc, Karen
    Houvras, Yariv
    Bumma, Naresh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans
    Hoffman, James E.
    Zonder, Jeffrey
    Zhou, Zheng-Yi
    Garcia-Horton, Viviana
    Fillbrunn, Mirko
    Wang, Hongjue
    Mattera, Matthew
    Ma, Wenxin
    Ma, Qiufei
    Inocencio, Timothy
    Xu, Yingxin
    Bergrath, Evelien
    Harnett, James
    Roccia, Tito
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    Houvras, Yariv
    Bumma, Naresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S274 - S275
  • [9] Incidence of second primary malignancies (SPMs) in patients in the US with triple-class-exposed (TCE) relapsed or refractory multiple myeloma (RRMM)
    Ge, Wenzhen
    Archambault, Alexi
    Delea, Thomas E.
    Lorenc, Karen Rodriguez
    Harnett, James
    Moynahan, Aaron P.
    Weycker, Derek
    Houvras, Yariv
    Kroog, Glenn S.
    Wu, Ning
    Hampp, Christian
    Ma, Qiufei
    Ailawadhi, Sikander
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 77 - 77
  • [10] Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)
    Ge, Wenzhen
    Archambault, Alexi
    Delea, Thomas E.
    Lorenc, Karen Rodriguez
    Harnett, James
    Moynahan, Aaron
    Weycker, Derek
    Houvras, Yariv
    Kroog, Glenn S.
    Wu, Ning
    Hampp, Christian
    Ma, Qiufei
    BLOOD, 2022, 140 : 10897 - 10899
12345